Protagonist Therapeutics (PTGX): Valuation Insights Ahead of Key Rusfertide Clinical Data at ASH Meeting [Yahoo! Finance]
Protagonist Therapeutics, Inc. (PTGX)
Last protagonist therapeutics, inc. earnings: 3/10 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.protagonist-inc.com
Company Research
Source: Yahoo! Finance
The company will share Phase 3 results, safety updates, and long-term extension findings with investors and clinicians. See our latest analysis for Protagonist Therapeutics. The recent momentum around Protagonist Therapeutics is impossible to ignore, with a year-to-date share price return of 101.7% amid anticipation for the December data release. Long-term investors have also been rewarded, as the total shareholder return over the past three years stands at a remarkable 914.5%. This reflects renewed optimism and increasing confidence in the company's growth prospects. If major biotech updates spark your curiosity, this is the perfect time to find your next standout opportunity with our See the full list for free. But after such an extraordinary run, the central question remains: Is Protagonist Therapeutics undervalued ahead of pivotal trial updates, or is all the future growth already reflected in today's price? Price-to-Earnings of 94x: Is it justified? Protagonist Therap
Show less
Read more
Impact Snapshot
Event Time:
PTGX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PTGX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PTGX alerts
High impacting Protagonist Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
PTGX
News
- Protagonist Therapeutics (NASDAQ:PTGX) had its price target raised by analysts at Citigroup Inc. from $96.00 to $98.00. They now have a "buy" rating on the stock.MarketBeat
- Protagonist Therapeutics (NASDAQ:PTGX) had its price target raised by analysts at JPMorgan Chase & Co. from $68.00 to $81.00. They now have an "overweight" rating on the stock.MarketBeat
- Protagonist Therapeutics (NASDAQ:PTGX) had its price target raised by analysts at Barclays PLC from $72.00 to $88.00. They now have an "overweight" rating on the stock.MarketBeat
- Protagonist Therapeutics (NASDAQ:PTGX) had its price target raised by analysts at Citizens Jmp from $69.00 to $102.00. They now have a "market outperform" rating on the stock.MarketBeat
- Protagonist Therapeutics (NASDAQ:PTGX) was given a new $88.00 price target on by analysts at Truist Financial Corporation.MarketBeat
PTGX
Earnings
- 11/6/25 - Miss
PTGX
Sec Filings
- 11/24/25 - Form 4
- 11/19/25 - Form 4
- 11/14/25 - Form SCHEDULE
- PTGX's page on the SEC website